SBIR Phase I: A High Throughput Microfluidics Platform to Measure Secretion from Single Cells

SBIR 第一阶段：测量单细胞分泌的高通量微流体平台

• 批准号: 1819932
• 负责人: Konstantinos Tsioris
• 金额: $ 22.5万
• 依托单位: ONECYTE BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2019-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1819932&HistoricalAwards=false
• 关键词: SBIR; Phase; Throughput; Microfluidics; Platform

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to develop single cell analysis technology to provide insight into cellular mechanisms, which has the potential to transform drug development and manufacturing. Single-cell analysis, or the ability to decipher cell-to-cell heterogeneity, is a limiting factor in biotechnology and clinical applications. This project aims to further develop a transformative platform technology for integrated single-cell analysis capable of addressing existing challenges with the current state-of-the-art. The platform will potentially shift the paradigm of drug development and manufacturing, enabling quick iteration and evaluation of new therapeutic compounds. This approach could significantly reduce the time and cost to bring new drugs to market and reduce the overall cost of treating patients, which is a substantial benefit to society. Beyond this initial application, this single-cell analysis platform could become a readily implemented research tool, enhancing our basic understanding of biology, facilitate engineering of cell function, as well as evaluating safety and efficacy of new drugs and treatments.This SBIR Phase I project proposes to develop a robust and cost effective commercial prototype technology platform for integrated single-cell analysis. A key feature of the platform technology is the unprecedented sensitivity in measuring quantitatively secreted molecules from single cells. This is achieved by incubating single cells in extremely small volumes, and enabling analytics on an unprecedented scale in these microscopic bioreactors. The proposed work will lead to the development of a consumable prototype microfluidic chip, enabling quick and resource efficient adaptation of the platform to the marketplace. The proposed prototype will be validated through relevant studies, addressing a confirmed market need in cell line development. Commercial adaptation of this prototype will potentially provide deep insight into biological and physiological processes on a single-cell level, and transform drug development and manufacturing, therapeutic treatment, as well as clinical diagnostics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）项目的更广泛的影响/商业潜力是开发单细胞分析技术，以洞悉细胞机制，这有可能改变药物开发和制造。单细胞分析或破译细胞到细胞异质性的能力是生物技术和临床应用的限制因素。该项目旨在进一步开发一种用于集成的单细胞分析的变革性平台技术，能够通过当前的最新面临解决现有的挑战。该平台将有可能改变药物开发和制造的范式，从而快速迭代并评估新的治疗化合物。这种方法可能会大大减少将新药带入市场并降低治疗患者的总体成本的时间和成本，这对社会是一个很大的好处。除了这一初步应用之外，这个单细胞分析平台还可以成为一种容易实现的研究工具，增强了我们对生物学的基本理解，促进了细胞功能的工程，并评估了新药物和治疗的安全性和功效。该SBIR阶段I阶段项目建议开发出可靠的和有效的集成单细胞分析的商业原型技术平台。平台技术的关键特征是在测量单个细胞定量分泌的分子方面的空前灵敏度。这是通过在极小体积中孵育单个细胞来实现的，并在这些微观生物反应器中以前所未有的规模启用分析。拟议的工作将导致开发可消耗的原型微流体芯片，从而使平台能够快速有效地适应市场。拟议的原型将通过相关研究验证，以满足细胞系开发中确认的市场需求。该原型的商业适应性将有可能在单细胞水平上深入了解生物学和生理过程，并改变药物开发和制造，治疗治疗以及临床诊断。这项奖项反映了NSF的法定任务，并被认为是通过基金会的知识绩效和广泛影响的评估来评估NSF的法定任务。